- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00482222
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with monoclonal antibodies before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective with or without cetuximab in treating liver metastases caused by colorectal cancer.
PURPOSE: This randomized phase III trial is studying combination chemotherapy to compare how well it works when given with or without cetuximab before and after surgery in treating patients with resectable liver metastases caused by colorectal cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Geneesmiddel: fluoruracil
- Geneesmiddel: leucovorine calcium
- Procedure: adjuvante therapie
- Procedure: neoadjuvante therapie
- Geneesmiddel: oxaliplatine
- Procedure: beoordeling van de kwaliteit van leven
- Geneesmiddel: capecitabine
- Ander: studie van sociaaleconomische en demografische variabelen
- Biologisch: cetuximab
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Compare progression-free survival of patients with resectable colorectal liver metastases treated with neoadjuvant and adjuvant combination chemotherapy with vs without cetuximab.
Secondary
- Compare the overall survival of patients treated with these regimens.
- Compare the quality of life of patients treated with these regimens.
- Compare the cost effectiveness of these regimens in these patients.
OUTLINE: This is a prospective, randomized, multicenter, open-label study. Patients are stratified according to participating center and assigned chemotherapy regimen. Patients are randomized to 1 of 2 treatment arms.
Neoadjuvant therapy:
Arm I: Patients receive 1 of the following chemotherapy regimens:
- OxMdG: Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- CAPOX: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Arm II: Patients receive 1 of the following regimens:
- OxMdG + cetuximab: Patients receive cetuximab IV over 1-2 hours on day 1 and OxMdG chemotherapy as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- CAPOX + cetuximab: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and CAPOX chemotherapy as in arm I. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- Surgery: Beginning 2-6 weeks after completion of chemotherapy, patients in both arms undergo liver resection.
Adjuvant therapy: Beginning 4-8 weeks after completion of surgery, patients receive treatment (OxMdG or CAPOX with or without cetuximab) as in arm I or II of neoadjuvant therapy.
- Arm I: Treatment with OxMdG repeats every 2 weeks for up to 6 courses and treatment with CAPOX repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Treatment with OxMdG + cetuximab repeats every 2 weeks for up to 6 courses and treatment with CAPOX + cetuximab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 12 weeks during chemotherapy, at completion of study treatment, every 3 months for 1 year, and then every 6 months thereafter.
Cost per life year and per quality-adjusted life year is assessed at baseline, every 12 weeks during treatment, and then at 3, 5, and 10 years.
After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Louisa Little
- Telefoonnummer: 02380795154
Studie Locaties
-
-
England
-
Basildon, England, Verenigd Koninkrijk, SS16 5NL
- Werving
- Basildon University Hospital
-
Contact:
- Pauline Leonard, MD
- Telefoonnummer: 44-1702-435-555
-
Basingstoke, England, Verenigd Koninkrijk, RG24 9NA
- Werving
- Basingstoke and North Hampshire NHS Foundation Trust
-
Contact:
- Charlotte Rees, MD
- Telefoonnummer: 44-125-631-4793
-
Bournemouth, England, Verenigd Koninkrijk, BH7 7DW
- Werving
- Royal Bournemouth Hospital
-
Contact:
- Tamas Hickish, MD
- Telefoonnummer: 44-1202-303-626
- E-mail: tamas.hickish@rbch.nhs.uk
-
Cambridge, England, Verenigd Koninkrijk, CB2 0QQ
- Werving
- Addenbrooke's Hospital
-
Contact:
- Pippa Corrie, PhD, FRCP
- Telefoonnummer: 44-1223-274-401
- E-mail: pippa.corrie@addenbrookes.nhs.uk
-
Guildford, England, Verenigd Koninkrijk, GU2 7XX
- Werving
- St. Luke's Cancer Centre at Royal Surrey County Hospital
-
Contact:
- Sharadah Essapen, MD
- Telefoonnummer: 44-1483-571-122
-
Liverpool, England, Verenigd Koninkrijk, L9 7AL
- Werving
- Aintree University Hospital
-
Contact:
- Graeme J. Poston, MD
- Telefoonnummer: 44-151-525-5980
- E-mail: graeme.poston@aintree.nhs.uk
-
Liverpool, England, Verenigd Koninkrijk, L9 7AL
- Werving
- Royal Liverpool University Hospital
-
Contact:
- Paula Ghaneh, MD
-
London, England, Verenigd Koninkrijk, SW3 6JJ
- Werving
- Royal Marsden - London
-
Contact:
- David Cunningham, MD
- Telefoonnummer: 44-20-8661-3156
-
London, England, Verenigd Koninkrijk, EC1A 7BE
- Werving
- Saint Bartholomew's Hospital
-
London, England, Verenigd Koninkrijk, W6 8RF
- Werving
- Charing Cross Hospital
-
Contact:
- Charles P. Lowdell, MD, BSc, MBBS, FRCP, FRCR
- Telefoonnummer: 44-208-383-0576
- E-mail: charles.lowdell@imperial.nhs.uk
-
London, England, Verenigd Koninkrijk, NW3 2PF
- Werving
- UCL Cancer Institute
-
Contact:
- Astrid Mayer, MD
- Telefoonnummer: 44-207-794-0500
- E-mail: a.mayer@ucl.ac.uk
-
Merseyside, England, Verenigd Koninkrijk, CH63 4JY
- Werving
- Clatterbridge Centre for Oncology
-
Newport, England, Verenigd Koninkrijk, PO30 5TG
- Werving
- St. Mary's Hospital
-
Contact:
- Christopher Baughan, MD
- Telefoonnummer: 44-1983-524-081
-
Nottingham, England, Verenigd Koninkrijk, NG5 1PB
- Werving
- Cancer Research Centre at Weston Park Hospital
-
Contact:
- J. Hornbuckle, MD
- Telefoonnummer: 44-115-969-1169 ext. 47599
-
Poole Dorset, England, Verenigd Koninkrijk, BH15 2JB
- Werving
- Dorset Cancer Centre
-
Contact:
- Tamas Hickish, MD
- Telefoonnummer: 44-1202-442-532
-
Salisbury, England, Verenigd Koninkrijk, SP2 8BJ
- Werving
- Salisbury District Hospital
-
Southampton, England, Verenigd Koninkrijk, SO16 6YD
- Werving
- Southampton General Hospital
-
Contact:
- John N. Primrose, MD
- Telefoonnummer: 44-23-8079-6144
- E-mail: j.n.primrose@soton.ac.uk
-
Sutton, England, Verenigd Koninkrijk, SM2 5PT
- Werving
- Royal Marsden - Surrey
-
Westcliff-On-Sea, England, Verenigd Koninkrijk, SS0 0RY
- Werving
- Southend University Hospital NHS Foundation Trust
-
Contact:
- Pauline Leonard, MD
- Telefoonnummer: 44-1702-435-555
-
Worthing, England, Verenigd Koninkrijk, BN11 2DH
- Werving
- Worthing Hospital
-
Contact:
- Andrew Webb, MD
- Telefoonnummer: 44-1903-205-111
-
-
Wales
-
Cardiff, Wales, Verenigd Koninkrijk, CF14 2TL
- Werving
- Velindre Cancer Center at Velindre Hospital
-
Contact:
- Timothy Maughan, MD
- Telefoonnummer: 44-2920-316-904
-
Cardiff, Wales, Verenigd Koninkrijk, CF14 4XW
- Werving
- University Hospital of Wales
-
Contact:
- Timothy Maughan, MD
- Telefoonnummer: 44-2920-316-904
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Histologically* or radiologically confirmed primary adenocarcinoma of the colon or rectum
- Advanced and/or metastatic disease NOTE: *Liver metastases should not be biopsied
Must have potentially resectable liver metastases present, as defined by any of the following:
- Metachronous metastases AND complete resection of the primary tumor without gross or microscopic evidence of residual disease (R0)
- Synchronous metastases AND R0 resection of the primary tumor > 1 month before study entry
- Synchronous metastases with sufficient evidence (e.g., by CT scan or diagnostic laparoscopy) that both the primary tumor and the liver metastases can be completely resected during the same procedure and resection of primary tumor can be delayed for 3-4 months
- Suboptimally resectable disease (i.e., potentially resectable disease with compromise of the resection margins)
- No detectable extrahepatic tumor that cannot be completely resected
- Unidimensionally measurable disease
- No brain metastases
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- WBC ≥ 4,000/mm³
- ANC ≥ 1,500/mm³
- Platelet count > 150,000/mm³
- Bilirubin ≤ 1.25 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 5 times ULN
- AST or ALT ≤ 3 times ULN
- Creatinine clearance > 50 mL/min OR glomerular filtration rate > 50 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
- No psychiatric or neurological condition that would preclude study compliance
- No partial or complete bowel obstruction
- No preexisting neuropathy > grade 1
- No other prior or concurrent malignant disease that, in the opinion of the investigator, would preclude study treatment
- No concurrent severe uncontrolled medical illness (including poorly-controlled angina or myocardial infarction within the past 3 months) that would preclude study treatment
- No known hypersensitivity reaction to any of the components of the study drugs
PRIOR CONCURRENT THERAPY:
- No prior systemic chemotherapy for metastatic disease
- More than 6 months since prior adjuvant chemotherapy comprising fluorouracil, leucovorin calcium, capecitabine, or irinotecan hydrochloride
- More than 1 month since prior rectal chemoradiotherapy comprising fluorouracil and leucovorin calcium
- No concurrent contraindicated medication
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: OxMdG / IrMdG chemotherapy
OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
|
|
Experimenteel: OxMdG / IrMdG chemotherapy with cetuximab
OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Progression-free survival
Tijdsspanne: end of study
|
end of study
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Algemeen overleven
Tijdsspanne: einde studie
|
einde studie
|
Response rate before surgery as assessed by RECIST criteria
Tijdsspanne: end of study
|
end of study
|
Pathological resection status
Tijdsspanne: end of study
|
end of study
|
Toxicity
Tijdsspanne: end of study
|
end of study
|
Quality of life as assessed by the EQ-5D, EORTC QLQ-C30, and EORTC QLQ-LMC21
Tijdsspanne: end of study
|
end of study
|
Cost effectiveness
Tijdsspanne: end of study
|
end of study
|
Safety
Tijdsspanne: end of study
|
end of study
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: John N. Primrose, MD, University Hospital Southampton NHS Foundation Trust
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Pathologische processen
- Neoplasmata
- Neoplasmata per site
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Colon Ziekten
- Darmziekten
- Intestinale neoplasmata
- Rectale ziekten
- Neoplastische processen
- Colorectale neoplasmata
- Neoplasma metastase
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Beschermende middelen
- Antineoplastische middelen, immunologisch
- Micronutriënten
- Vitaminen
- Calciumregulerende hormonen en middelen
- Tegengif
- Vitamine B-complex
- Fluoruracil
- Capecitabine
- Oxaliplatine
- Leucovorin
- Calcium
- Levoleucovorine
- Cetuximab
Andere studie-ID-nummers
- CDR0000549541
- USCTU-4351
- USCTU-EPOC
- EUDRACT-2006-003121-82
- ISRCTN22944367
- EU-20732
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Colorectale kanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op fluoruracil
-
Peking Union Medical College HospitalWervingRectale kanker | Darmkanker | Chemotherapie-effect | PTC | Exon-mutatieChina
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital &... en andere medewerkersOnbekendNasofarynxcarcinoomChina
-
CStone PharmaceuticalsActief, niet wervendInoperabel lokaal gevorderd, recidiverend of gemetastaseerd slokdarmplaveiselcelcarcinoomChina
-
Actavis Inc.VoltooidActinische keratoseVerenigde Staten
-
The Netherlands Cancer InstituteVoltooid
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchVoltooid
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer FundVoltooid
-
Boston UniversityWervingOppervlakkig basaalcelcarcinoom | Plaveiselcelcarcinoom in situVerenigde Staten
-
The Cleveland ClinicNational Cancer Institute (NCI)BeëindigdActinische keratose | Orgaan- of weefseltransplantatie; complicatiesVerenigde Staten
-
Singapore National Eye CentreSingapore Eye Research Institute; Nanchang UniversityVoltooidGlaucoom | Wond genezen | TrabeculectomieSingapore